anti fak (Proteintech)
Proteintech is a verified supplier 
96
Structured Review
Proteintech
anti fak
Anti Fak, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 185 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+fak/FAK+Antibody/10__1038_slash_s41419___026___09318___4-58-69-74
Average 96 stars, based on 185 article reviews
Anti Fak, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 185 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+fak/FAK+Antibody/10__1038_slash_s41419___026___09318___4-58-69-74
Average 96 stars, based on 185 article reviews
anti fak - by Bioz Stars,
2026-10
96/100 stars
Images
Related Articles
Western Blot:Article Title: AKAP2 is required for assembly of cytoskeletal signaling complexes that promote growth and metastasis of triple-negative breast cancer. Article Snippet: .. Primary antibodies used for immunoblotting include: anti-AKAP2 (1:1000, Novus Biological, NB-100-61604); anti-e-cadherin (1:1000, BD Transduction, 610181); anti-ZEB1 (1:1000, CST, 70512T); anti-β-actin (1:1000, CST, 4970S); antivimentin (1:1000, Santa Cruz Biotechnology, sc-6260); anti-Streptavidin-HRP (1:10000, abcam 7403); Article Title: AKAP2 is required for assembly of cytoskeletal signaling complexes that promote growth and metastasis of triple-negative breast cancer Article Snippet: .. Primary antibodies used for immunoblotting include: anti-AKAP2 (1:1000, Novus Biological, NB-100-61,604); anti-e-cadherin (1:1000, BD Transduction, 610181); anti-ZEB1 (1:1000, CST, 70512T); anti-β-actin (1:1000, CST, 4970S); anti-vimentin (1:1000, Santa Cruz Biotechnology, sc-6260); anti-Streptavidin-HRP (1:10,000, abcam 7403); Incubation:Article Title: Targeting NSUN5-mediated m5C-RNA modification overcomes sunitinib resistance in renal cell carcinoma by suppressing Fibronectin/PI3K/AKT signaling Article Snippet: Cells were subjected to lysis utilizing RIPA buffer (Beyotime, China) with the addition of protease inhibitors PMSF (MedChemExpress [MCE], China), and quantification of protein concentrations was performed employing the bicinchoninic acid (BCA) assay (Beyotime). .. Proteins were separated by 10% SDS-PAGE, transferred onto PVDF membranes, and incubated overnight at 4 °C with different primary antibodies, including anti-NSUN5 (1:2000; #ab121633; RRID: AB_11129930; Abcam, USA), anti-PI3K (1:2000; #ab302958; Abcam), anti-AKT (1:5000; #4691T; Cell Signaling Technology [CST], USA), anti-p-AKT (1:5000; #4060T; RRID: AB_2315049; CST), anti-pPI3K (1:2000; #4228T; CST), anti-FN1 (1:10000; #15613-1-AP; RRID: AB_2105691; Proteintech, China), antiALYREF (1:1000; #16690-1-AP; RRID: AB_2878300; Proteintech), anti-YBX1 (1:10000; #20339-1-AP; RRID: AB_10665424; Proteintech), Cell-Signaling:Article Title: Targeting NSUN5-mediated m5C-RNA modification overcomes sunitinib resistance in renal cell carcinoma by suppressing Fibronectin/PI3K/AKT signaling Article Snippet: Cells were subjected to lysis utilizing RIPA buffer (Beyotime, China) with the addition of protease inhibitors PMSF (MedChemExpress [MCE], China), and quantification of protein concentrations was performed employing the bicinchoninic acid (BCA) assay (Beyotime). .. Proteins were separated by 10% SDS-PAGE, transferred onto PVDF membranes, and incubated overnight at 4 °C with different primary antibodies, including anti-NSUN5 (1:2000; #ab121633; RRID: AB_11129930; Abcam, USA), anti-PI3K (1:2000; #ab302958; Abcam), anti-AKT (1:5000; #4691T; Cell Signaling Technology [CST], USA), anti-p-AKT (1:5000; #4060T; RRID: AB_2315049; CST), anti-pPI3K (1:2000; #4228T; CST), anti-FN1 (1:10000; #15613-1-AP; RRID: AB_2105691; Proteintech, China), antiALYREF (1:1000; #16690-1-AP; RRID: AB_2878300; Proteintech), anti-YBX1 (1:10000; #20339-1-AP; RRID: AB_10665424; Proteintech), |
![Q209R preferentially engages FAK‐YAP signaling. (A) Western blot analysis of GNAQ, BAP1, Melan‐A, p‐ERK1/2 (Thr202/Tyr204), ERK1/2, FRA1, p‐AKT (Ser473), AKT, p‐4EBP1 (Ser65), and 4EBP1 expression in mouse UM cell lines harboring GNAQ Q209R or GNAQ Q209L . HSP90 was used as an internal loading control. (B) Quantification of the relative ratio between p‐AKT (Ser473) and AKT in Q209R and Q209L UM cell lines from (A). (C) Quantification of the relative ratio between p‐4EBP1 (Ser65) and 4EBP1 in Q209R and Q209L UM cell lines from (A). (D) Western blot analysis of p‐FAK <t>(Tyr397),</t> FAK, p‐YAP (Ser127), and YAP in mouse UM cell lines harboring GNAQ Q209R or GNAQ Q209L . HSP90 was used as an internal loading control. (E) Quantification of the relative ratio between p‐FAK (Tyr397) and FAK in Q209R and Q209L UM cell lines from (D). (F) Quantification of the relative ratio between p‐YAP (Ser127) and YAP in Q209R and Q209L UM cell lines from (D). Orthotopic tumor‐derived cell lines (QBM12.1 [Q209R], QBM12.3 [Q209R], QBM24 [Q209R], QBM45 [Q209L], QBM47 [Q209L]) and liver metastatic lines (QBM12L [Q209R], QBM12L2 [Q209R], QBM51L [Q209L], QBM53L [Q209L]) were used in A–F. (G) Representative IHC images showing YAP expression in primary tumors from Gnaq CA ; Bap1 CKO ; Myc CKI mice harboring either GNAQ Q209R or GNAQ Q209L . (H) Quantification of the nuclear‐to‐cytoplasmic YAP intensity ratio (H‐score) among primary tumors from Gnaq CA ; Bap1 CKO ; Myc CKI mice harboring either GNAQ Q209R or GNAQ Q209L . (I) Representative IHC images showing YAP expression in liver metastasis derived from intrasplenic transplantation of mouse UM cell lines harboring GNAQ Q209R or GNAQ Q209L . (J) Quantification of nuclear YAP intensity (H‐score) among liver metastasis derived from intrasplenic transplantation of mouse UM cell lines harboring GNAQ Q209R or GNAQ Q209L .](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_5764/pmc13635764/pmc13635764__PCMR-39-0-g001.jpg)